Growth Metrics

Harmony Biosciences Holdings (HRMY) Income from Continuing Operations (2019 - 2025)

Historic Income from Continuing Operations for Harmony Biosciences Holdings (HRMY) over the last 7 years, with Q3 2025 value amounting to $50.9 million.

  • Harmony Biosciences Holdings' Income from Continuing Operations rose 1035.3% to $50.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $157.7 million, marking a year-over-year increase of 4438.4%. This contributed to the annual value of $117.5 million for FY2024, which is 178.37% up from last year.
  • Per Harmony Biosciences Holdings' latest filing, its Income from Continuing Operations stood at $50.9 million for Q3 2025, which was up 1035.3% from $39.8 million recorded in Q2 2025.
  • Over the past 5 years, Harmony Biosciences Holdings' Income from Continuing Operations peaked at $87.9 million during Q3 2022, and registered a low of -$9.6 million during Q3 2021.
  • Its 5-year average for Income from Continuing Operations is $30.6 million, with a median of $29.5 million in 2023.
  • The largest annual percentage gain for Harmony Biosciences Holdings' Income from Continuing Operations in the last 5 years was 5238518.52% (2021), contrasted with its biggest fall of 60392.88% (2021).
  • Harmony Biosciences Holdings' Income from Continuing Operations (Quarter) stood at $19.1 million in 2021, then skyrocketed by 154.53% to $48.5 million in 2022, then crashed by 72.81% to $13.2 million in 2023, then surged by 62.84% to $21.5 million in 2024, then skyrocketed by 136.86% to $50.9 million in 2025.
  • Its last three reported values are $50.9 million in Q3 2025, $39.8 million for Q2 2025, and $45.6 million during Q1 2025.